Pharmaceuticals

Global Liver Cancer Therapeutics Market Size Projected to Reach $5.45 Billion During the Forecast Period

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Liver Cancer Therapeutics Industry Compare Between 2025 And 2029?

The liver cancer therapeutics market size has experienced significant growth in recent years. This market is projected to expand from $2.52 billion in 2024 to $2.94 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 16.8%. Historically, this growth can be attributed to factors such as increased funding from government and non-profit organizations, a global rise in healthcare expenditure, broadening health insurance coverage in developing countries, an aging worldwide population, and the increasing prevalence of obesity and diabetes.

The liver cancer therapeutics market size is anticipated to undergo significant expansion in the coming years, with projections indicating growth to ” $5.45 billion in 2029, achieving a compound annual growth rate (CAGR) of 16.7%. This growth over the forecast period stems from factors such as the increasing global incidence of liver cancer, the high prevalence of hepatitis B and C infections, a rise in alcohol-related liver disease, the growing number of non-alcoholic fatty liver disease cases, and the broader adoption of immunotherapy approaches. Noteworthy trends expected during this period include the integration of AI and ML into drug discovery processes, the utilization of big data and real-world evidence in trials, the advancement of imaging technologies, the adoption of minimally invasive diagnostic tools, and the use of telemedicine and digital health for oncology follow-up care.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24283&type=smp

What Are The Main Drivers Boosting The Liver Cancer Therapeutics Industry’s Expansion?

The liver cancer therapeutics market is projected to expand due to the increasing incidence of hepatitis B infections. Hepatitis B, a viral illness caused by the hepatitis B virus (HBV), primarily impacts the liver, potentially causing both short-term and long-term health issues, including liver cancer. The rise in these infections is partly attributable to an increase in injection drug use, which facilitates the virus’s spread through shared contaminated needles and syringes. Liver cancer therapeutics are essential for hepatitis B infections because persistent chronic infection can lead to continuous liver inflammation and cell damage, significantly elevating the likelihood of developing malignant liver conditions over time. For instance, a report published by the World Health Organization (WHO) in April 2024 indicated that there were over 254 million hepatitis B-positive individuals globally in 2022, with 1.2 million new cases identified. Furthermore, hepatitis B was the cause of 83% of the 1.3 million viral hepatitis-related deaths worldwide. Consequently, the growing number of hepatitis B infections is set to stimulate the growth of the liver cancer therapeutics market.

What Are The Different Segment Classifications Within The Liver Cancer Therapeutics Market?

The liver cancer therapeutics market covered in this report is segmented –

1) By Type: Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, Other Types

2) By Therapy Type: Targeted Therapy, Immunotherapy, Chemotherapy, Radiation Therapy, Other Therapy Types

3) By Distribution Channel Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End-Users: Pediatrics, Adults

Subsegments:

1) By Hepatocellular Carcinoma: Localized Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma

2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma

3) By Hepatoblastoma: Standard-Risk Hepatoblastoma, High-Risk Hepatoblastoma, Metastatic Hepatoblastoma

4) By Other Types: Fibrolamellar Carcinoma, Angiosarcoma Of The Liver, Hemangiosarcoma

Which Competitive Trends Are Defining The Liver Cancer Therapeutics Market Structure?

Leading companies in the liver cancer therapeutics market are focused on creating innovative therapies, like prescription immunotherapy medications, to provide long-lasting benefits. Prescription immunotherapy medications are drugs that either boost or suppress the body’s immune system to help fight specific diseases, such as cancer or chronic infections, by precisely targeting and modulating immune responses. For example, in April 2025, Bristol Myers Squibb, a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment for adult patients with hepatocellular carcinoma (HCC), the most prevalent primary liver cancer, when it is either incurable or has spread. The distinctive feature of this product’s approval is based on the findings from the global Phase 3 randomized, open-label CheckMate-9DW trial. In this study, patients with metastatic or incurable HCC who had not previously received systemic therapy were randomized to a treatment plan of Opdivo plus Yervoy in addition to the investigator’s choice of tyrosine kinase inhibitor monotherapy (lenvatinib or sorafenib). The combination therapy exhibited statistically significant enhancements in overall survival (OS) and overall response rate (ORR) when compared to the comparator arm, making it the sole trial supporting an FDA approval that has shown superior results in this setting.

Which Leading Companies Dominate The Liver Cancer Therapeutics Market Share?

Major companies operating in the liver cancer therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca PLC, Amgen Inc., Eli Lilly and Company , Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Ipsen, Exelixis Inc., BeiGene Ltd., Hutchmed, Celgene Corporation, Zymeworks Inc., Can-Fite BioPharma, Onyx Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/liver-cancer-therapeutics-global-market-report

How Do Regional Market Performances Compare Within The Liver Cancer Therapeutics Industry?

North America was the largest region in the liver cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Liver Cancer Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24283&type=smp

Browse Through More Reports Similar to the Global Liver Cancer Therapeutics Market 2025, By The Business Research Company

Blood Pressure Monitoring Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-pressure-monitoring-devices-global-market-report

Liver Diseases Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Liver Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795